Therefore, we believe that GIT1 may be a carcinogen of HNSCC and promote the occurrence and development of tumour, or may be a potential target for HNSCC therapy by inhibiting GIT1. This evidence concerns the gene GIT1 and head and neck squamous cell carcinoma.